“Diabetic Foot Ulcers Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Foot Ulcers Market.
The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Diabetic Foot Ulcers Pipeline Report:
- Companies across the globe are diligently working toward developing novel Diabetic Foot Ulcers treatment therapies with a considerable amount of success over the years.
- Diabetic Foot Ulcers companies working in the treatment market are Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corporation, MediWound, Paracrine, INC., NovaLead Pharma, and others, are developing therapies for the Diabetic Foot Ulcers treatment
- Emerging Diabetic Foot Ulcers therapies in the different phases of clinical trials are- TOP-N53, YP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, Galnobax, and others are expected to have a significant impact on the Diabetic Foot Ulcers market in the coming years.
- In the year 2023, the Phase 3 clinical study of Stempeucel®-DFU, a patented allogeneic mesenchymal stromal cell product candidate, in patients with non-healing diabetic foot ulcers has concluded, according to a press release from Stempeutics Research, a subsidiary of Manipal Education and Medical Group (MEMG). Depending on where the ulcer is, the drug is delivered by intramuscular, intradermal, or subcutaneous routes. Phase 3 trial has received DCGI approval.
- According to Huang, et al.’s analysis, “Stem Cell Treatment for Diabetic Foot Ulcers: A Meta-analysis of Randomised Clinical Trials,” published in May 2023, the stem cell group had a higher ulcer healing rate than the control group (odds ratio [OR], 5.16; 95% confidence interval [CI], 3.60-7.40; P .00001). Particularly, the mononuclear cell and mesenchymal stem cell groups showed faster healing rates for ulcers (OR, 3.98; 95% CI, 2.05-7.73; P .0001; and OR, 12.85; 95% CI, 4.36-37.82; P .0001, respectively).
Diabetic Foot Ulcers Overview
One of the most frequent consequences of people with poorly controlled diabetes mellitus is a diabetic foot ulcer, which is an open sore or wound. It typically develops on the bottom of the foot in about 15% of diabetic individuals, which can result in lower extremity amputation.
Get a Free Sample PDF Report to know more about Diabetic Foot Ulcers Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-pipeline-insight
Emerging Diabetic Foot Ulcers Drugs Under Different Phases of Clinical Development Include:
- TOP-N53: Topadur Pharma
- YP-006TK: Cynata Therapeutics
- TWB-103: Transwell Biotech
- AUP 16: Aurealis Therapeutics
- CSTC 1: Charsire Biotechnology Corporation
- APO-2: Aposcience
- ILP100: Ilya Pharma
- MBN-101: Microbion Corporation
- EscharEx: MediWound
- Adipose-derived regenerative cells: Paracrine, INC.
- Galnobax: NovaLead Pharma
Route of Administration
Diabetic Foot Ulcers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Diabetic Foot Ulcers Pipeline Therapeutics Assessment
- Diabetic Foot Ulcers Assessment by Product Type
- Diabetic Foot Ulcers By Stage and Product Type
- Diabetic Foot Ulcers Assessment by Route of Administration
- Diabetic Foot Ulcers By Stage and Route of Administration
- Diabetic Foot Ulcers Assessment by Molecule Type
- Diabetic Foot Ulcers by Stage and Molecule Type
DelveInsight’s Diabetic Foot Ulcers Report covers around 34+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Diabetic Foot Ulcers product details are provided in the report. Download the Diabetic Foot Ulcers pipeline report to learn more about the emerging Diabetic Foot Ulcers therapies
Some of the key companies in the Diabetic Foot Ulcers Therapeutics Market include:
Key companies developing therapies for Diabetic Foot Ulcers are – Integra LifeSciences Corporation, Smith & Nephew, Tissue Regenix, Coloplast Corp, B. Braun Melsungen AG, 3M, Cardinal Health., ConvaTec Group Plc, Mölnlycke Health Care AB, and others.
Diabetic Foot Ulcers Pipeline Analysis:
The Diabetic Foot Ulcers pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Foot Ulcers with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Foot Ulcers Treatment.
- Diabetic Foot Ulcers key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Diabetic Foot Ulcers Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Foot Ulcers market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetic Foot Ulcers drugs and therapies
Diabetic Foot Ulcers Pipeline Market Drivers
- Rise in global prevalence of foot ulcers in diabetic patients, increasing research and development activities in the development of biologics, technological advancements are some of the important factors that are fueling the Diabetic Foot Ulcers Market.
Diabetic Foot Ulcers Pipeline Market Barriers
- However, high cost of the advanced wound care therapies, adverse effects associated with the drugs and other factors are creating obstacles in the Diabetic Foot Ulcers Market growth.
Scope of Diabetic Foot Ulcers Pipeline Drug Insight
- Coverage: Global
- Key Diabetic Foot Ulcers Companies: Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corporation, MediWound, Paracrine, INC., NovaLead Pharma, and others
- Key Diabetic Foot Ulcers Therapies: TOP-N53, YP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, Galnobax, and others
- Diabetic Foot Ulcers Therapeutic Assessment: Diabetic Foot Ulcers current marketed and Diabetic Foot Ulcers emerging therapies
- Diabetic Foot Ulcers Market Dynamics: Diabetic Foot Ulcers market drivers and Diabetic Foot Ulcers market barriers
Request for Sample PDF Report for Diabetic Foot Ulcers Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Diabetic Foot Ulcers Report Introduction |
|
2 |
Diabetic Foot Ulcers Executive Summary |
|
3 |
Diabetic Foot Ulcers Overview |
|
4 |
Diabetic Foot Ulcers- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Diabetic Foot Ulcers Pipeline Therapeutics |
|
6 |
Diabetic Foot Ulcers Late Stage Products (Phase II/III) |
|
7 |
Diabetic Foot Ulcers Mid Stage Products (Phase II) |
|
8 |
Diabetic Foot Ulcers Early Stage Products (Phase I) |
|
9 |
Diabetic Foot Ulcers Preclinical Stage Products |
|
10 |
Diabetic Foot Ulcers Therapeutics Assessment |
|
11 |
Diabetic Foot Ulcers Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Diabetic Foot Ulcers Key Companies |
|
14 |
Diabetic Foot Ulcers Key Products |
|
15 |
Diabetic Foot Ulcers Unmet Needs |
|
16 |
Diabetic Foot Ulcers Market Drivers and Barriers |
|
17 |
Diabetic Foot Ulcers Future Perspectives and Conclusion |
|
18 |
Diabetic Foot Ulcers Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services